Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4697-4708

  Narayanan, Bhagavathi A ^a   Doudican, Nicole A ^a   Park, Jeesun ^a   Xu, Dazhong ^a   Narayanan, Narayanan K ^a   Dasgupta, Ramanuj ^a   Mazumder, Amitabha ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

catenin; Multiple myeloma; Transcription; VEGF and DKK1; Wnt

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; BETA CATENIN REGULATED TRANSCRIPTION INHIBITOR 3; BETA CATENIN REGULATED TRANSCRIPTION INHIBITOR 5; DICKKOPF 1 PROTEIN; OXAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LEVEL; CELL MIGRATION; CELL PROLIFERATION; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; TRANSCRIPTION REGULATION; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MULTIPLE MYELOMA; OXAZOLES; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THIAZOLES; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WNT PROTEINS;

EID: 84872651192     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA and Anderson KC: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87: 1104-1112, 1996.
2. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, van der Neut R, Spaargaren M and Pals ST: Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 101: 6122-6127, 2004.
3. McWhirter JR, Neuteboom ST, Wancewicz EV, Monia BP, Downing JR and Murre C: Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia. Proc Natl Acad Sci USA 96: 11464-11469, 1999.
4. Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F and Dammacco F: A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 88: 176-185, 2003.
5. Van Den Berg DJ, Sharma AK, Bruno E and Hoffman R: Role of members of the Wnt gene family in human hematopoiesis. Blood 92: 3189-3202, 1998.
6. Kim Y, Schmidt M, Endo T, Lu D, Carson D and Schmidt-Wolf IG: Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model. In Vivo 25: 887-893, 2011.
7. 2+ pathways. Oncogene 18: 7860-7872, 1999.
8. You Z, Saims D, Chen S, Zhang Z, Guttridge DC, Guan KL, MacDougald OA, Brown AM, Evan G, Kitajewski J and Wang CY: Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol 157: 429-440, 2002.
9. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC and Carrasco DR: Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 104: 7516-7521, 2007.
10. Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, Munoz S, Grubbs B and Mundy GR: Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111: 2833-2842, 2008.
11. Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B and Shaughnessy JD Jr.: Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 113: 4319-30, 2009.
12. Kawano Y and Kypta R: Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116: 2627-2634, 2003.
13. Furlong MT and Morin PJ: Rare activation of the TCF/beta-catenin pathway in ovarian cancer. Gynecol Oncol 77: 97-104, 2000.
14. Giles RH, van Es JH and Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24, 2003.
15. Moon RT, Kohn AD, De Ferrari GV and Kaykas A: WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701, 2004.
16. Gonsalves FC, Klein K, Carson BB, Katz S, Ekas LA, Evans S, Nagourney R, Cardozo T, Brown AM and DasGupta R: An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci USA 108: 5954-5963, 2011.
17. Nardiello T, Jungbluth AA, Mei A, Diliberto M, Huang X, Dabrowski A, Andrade VC, Wasserstrum R, Ely S, Niesvizky R, Pearse R, Coleman M, Jayabalan DS, Bhardwaj N, Old LJ, Chen-Kiang S and Cho HJ: MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin Cancer Res 17: 4309-4319, 2011.
18. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B and Shaughnessy J Jr.: Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99: 1745-1757, 2002.
19. Narayanan BA, Narayanan NK, Davis L and Nargi D: RNA interference- mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther 5: 1117-1125, 2006.
20. Kim HN, Narayanan NK, Lasano S and Narayanan B: Modulation of PGE2-induced EP4 expression on snail signaling and the impact on epithelial-mesenchymal transition: significance of EP4 antagonism. Anticancer Res 31: 4347-4357, 2011.
21. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD Jr., Brennan C and Depinho RA: High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9: 313-325, 2006.
22. Qiang YW, Endo Y, Rubin JS and Rudikoff S: Wnt signaling in B-cell neoplasia. Oncogene 22: 1536-1545, 2003.
23. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI and Anderson KC: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15: 1950-1961, 2001.
24. Westendorf JJ, Kahler RA and Schroeder TM: Wnt signaling in osteoblasts and bone diseases. Gene 341: 19-39, 2004.
25. Glass DA, 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, and Karsenty G: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8: 751-764, 2005.
26. Ashihara E, Kawata E, Nakagawa Y, Shimazaski C, Kuroda J, Taniguchi K, Uchiyama H, Tanaka R, Yokota A, Takeuchi M, Kamitsuji Y, Inaba T, Taniwaki M, Kimura S and Maekawa T: beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res 15: 2731-2738, 2009.
27. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X and Richards WG: Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39: 754-766, 2006.
28. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A and Niehrs C: Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417: 664-667, 2002.
29. Di Raimondo F, Azzaro MP, Palumbo GA, Bagnato S, Stagno F, Giustolisi GM, Cacciola E, Sortino G, Guglielmo P and Giustolisi R: Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 15: 976-980, 2001.
30. Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC and Anderson KC: The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 62: 5019-5026, 2002.
31. Rajkumar SV: Thalidomide in multiple myeloma. Oncology (Williston Park) 14: 11-16, 2000.
32. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA and Greipp PR: Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 75:897-901, 2000.
33. Ribatti D, Vacca A, Nico B, Quondamatteo F, Ria R, Minischetti M, Marzullo A, Herken R, Roncali L and Dammacco F: Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 79:451-455, 1999.
34. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE and Kienast J: Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95: 2630-2636, 2000.
35. Vincent L, Jin DK, Karajannis MA, Shido K, Hooper AT, Rashbaum WK, Pytowski B, Wu Y, Hicklin DJ, Zhu Z, Bohlen P, Niesvizky R and Rafii S: Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells. Cancer Res 65: 3185-3192, 2005.